Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30129807 | 1.00 | FFAR1 (0.44) | FFAR1CYP19A1ESR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL451478 | 0.88 | CYP19A1 (0.41) | FFAR1CYP19A1ESR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL2154210 | 0.86 | SMN1; SMN2 (0.49) | FFAR1CYP19A1ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL7396264 | 0.84 | CYP19A1 (0.39) | FFAR1CYP19A1ESR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL28248935 | 0.82 | CYP19A1 (0.46) | FFAR1CYP19A1ESR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL28248440 | 0.82 | CYP19A1 (0.46) | FFAR1CYP19A1ESR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL30496165 | 0.82 | ALDH1A1 (0.49) | FFAR1CYP19A1ESR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL483697 | 0.82 | ALDH1A1 (0.49) | FFAR1CYP19A1ESR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL29278135 | 0.80 | NOTUM (0.35) | FFAR1CYP19A1ESR2ALDH1A1SMN1; SMN2 | |
| SCHEMBL84271 | 0.80 | PLAU (0.35) | FFAR1CYP19A1ESR2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113816964-B | Reversible ionic liquid for capturing carbon dioxide and synthesis method thereof | 中国科学院兰州化学物理研究所 | 2023-02-10 | — | — | CN | claimed |
| CN-110835361-A | Sialic acid glycosyl donor and preparation method and application thereof | 山东大学 | 2020-02-25 | — | — | CN | claimed |
| CN-105330565-A | Novel method for catalytically synthesizing cyanobenzene derivative through copper | UNIV HANGZHOU NORMAL | 2016-02-17 | — | — | CN | claimed |
| CN-105039447-A | Method for producing (S)-benzonitrile ethanol through candida | UNIV QINGDAO SCIENCE & TECHNOLOGY | 2015-11-11 | — | — | CN | claimed |
| CN-113816964-B | Reversible ionic liquid for capturing carbon dioxide and synthesis method thereof | 中国科学院兰州化学物理研究所 | 2023-02-10 | — | — | CN | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-111517902-B | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2022-06-14 | — | — | CN | disclosed |
| CN-110325531-B | Benzenesulfonamides and their use as therapeutic agents | 泽农医药公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-113816964-A | Reversible ionic liquid for capturing carbon dioxide and synthesis method thereof | 中国科学院兰州化学物理研究所 | 2021-12-21 | — | — | CN | disclosed |
| CN-111517902-A | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2020-08-11 | — | — | CN | disclosed |
| WO-2020155595-A1 | AEROBIC OXIDATION SYSTEM CONTAINING SULFINIC ACID, SULFONIC ACID OR DERIVATIVES THEREOF AND PHOTOCATALYTIC OXIDATION METHOD THEREFOR | 清华大学 | 2020-08-06 | — | — | WO | disclosed |
| EP-2906553-B1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-26 | — | — | EP | disclosed |
| US-20060014962-A1 | Thiadiazole compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-01-19 | — | — | US | disclosed |
| WO-2005090286-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-29 | — | — | WO | disclosed |
| EP-1550661-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-07-06 | — | — | EP | disclosed |
| WO-2002022584-A1 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-1084102-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | AstraZeneca AB (SE) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999062871-A1 | NEW 3-ARYL PROPIONIC ACID DERIVATIVES AND ANALOGS | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
| US-5633247-A | ANTIARRTHYMIA AGENT | MERCK & CO., INC. (US) | 1997-05-27 | — | — | US | disclosed |
| US-5206240-A | Antiarrhythmia agents | MERCK & CO., INC. (US) | 1993-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014962-A1 | Thiadiazole compound and use thereof | CBR3, TH, CYP2E1 | FFAR1 3941/4885CYP19A1 454/4885ESR2 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.